

1600
H. Davis
PATENT 0100

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER OF PATENTS, WASHINGTON, DC 20231, ON THE DATE INDICATED BELOW.

BY:

Carol Taylor

DATE: November 0, 2000



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:	Patent Application of Darwin J. Prockop <i>et al.</i>	:	Group Art Unit: 1633
Appln. No.:	09/028,395	:	Examiner: Janet M. Kerr
Filed:	February 24, 1998	:	Attorney Docket
For:	ISOLATED STROMAL CELLS FOR USE IN THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM	:	No. 9598-32US (209598.0032) AUHS-318

RESPONSE TO OFFICE ACTION

This Response responds to the Office Action dated May 24, 2000 (Paper No. 12), sent in connection with the above-referenced application. This Amendment is being timely filed in view of the accompanying petition for a Three Month Extension of Time, and associated fee, which extends the time for a response to the Office Action to and through November 24, 2000.

REMARKS

The present application is a continuation-in-part of PCT Application No. US/PCT9604407, filed on March 28, 1996, which is a continuation of U.S. Application No. 08/412,066, filed on March 28, 1995, all of which are entitled to priority under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 60/006,627, filed on November 13, 1995.

The present invention relates to novel isolated marrow stromal cells ("MSCs") for use in treatment of a central nervous system ("CNS") disease, disorder or condition. The invention discloses methods comprising administering isolated marrow stromal cells into the CNS of a human patient thereby effecting treatment of a disease, disorder or condition thereof. Moreover, the stromal cells may be cultured *in vitro*,